DC Chemicals · Product datasheet

Vafidemstat (ORY-2001) — Datasheet

CAT. NO. DC11106

Product page and current package options

Parameter	Value
Chemical Name	Vafidemstat
CAS No.	1357362-02-7
Synonyms	Vafidemstat;LZ82JLT4UP;Vafidemstat [INN];XBBRLCXCBCZIOI-DLBZAZTESA-N;BCP29383;5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine;5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine;1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-;ORY-2001;Vafidemstat (ORY-2001)?;SCHEMBL528204;CS-0058593;AKOS040742807;vafidemstatum;5-({[(1R,2S)-2-[4-(benzyloxy)phenyl]cyclopropyl]amino}methyl)-1,3,4-oxadiazol-2-amine;(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine;UNII-LZ82JLT4UP;1357362-02-7;MS-25100;1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-;HY-112623;5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine;BDBM50594947;DA-58938;ORY 2001; ORY-2001; ORY2001;G16394;CHEMBL4802155
Formula	C19H20N4O2
M.Wt	336.387703895569
SMILES	O1C(N)=NN=C1CN[C@@H]1C[C@H]1C1C=CC(=CC=1)OCC1C=CC=CC=1
Purity	>98%
Storage	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

Vafidemstat is a dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor.

In Vitro

Vafidemstat (ORY-2001), a dual LSD1/MAO-B inhibitor, is a novel epigenetic agent for the treatment of neurodegenerative diseases. LSD1 is a protein that participates in transcription regulation complexes; its modulation can be used to tweak transcriptional imbalances in neurodegenerative disease and redress neuroinflammation and cognitive deficit[1]. Vafidemstat (ORY-2001) can be used in the treatment of Alzheimer's disease[2].

In Vivo

No in vivo data are provided in the current product source. Contact us for further information.

Target

LSD1/MAO-B[1]

References & source

[1]. ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer’s and Parkinson’s diseases

[2]. ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2018.

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.